News Focus
News Focus
icon url

sukus

12/22/19 10:18 AM

#256595 RE: Bright Boy #256593

There is a secret sauce and they were patented.
icon url

KIPK

12/22/19 10:18 AM

#256596 RE: Bright Boy #256593

Wrong - Everything Is Patentable, Including a Process such thing as a Manufacturing Process...

P.S. This Is Not a Pill......
icon url

marzan

12/22/19 10:43 AM

#256597 RE: Bright Boy #256593

same thing happened with Amarin's Vascepa fish oil pill that people claim no secret sauce. But FDA approved it and is about to load all Amarin's secret sauce patents into FDA's Orange Book by the end of next month. Once on the Orange Book, Rx is good for several years and duplicators have to pay treble damages infringing the patents. EPA molecule has been in existence for millions of years ever since the human evolution is in place but Amarin had it under the Method of Administering patents. It also got under Composition of the secret sauce patents that AZN couldn't invalidate it. Now the generics are trying very hard but they can't prove Obviousness in the courts even though the entire world is thinking now that it is very obvious EPA protects the heart like it is very obvious immunotherapy can cure cancers. But only Amarin proved it with the Reduce It trial under 8000+ patients for over 5 yrs. Amarin isolated EPA from the Omega3 mixtures, purified it, concentrated it, and administer at 4gm a day dose to prove it protects the heart. Same thing here dendritic cells isolated, pulsed with tumor antigens, concentrated to be more potent, formulated to be a vaccine, administered at specific intervals. NWBO went one step further they have a second secret sauce called Direct but doing the autologous process not outside but inside the tumor as it uptakes all the antigens from within the tumor. Like Sukus says LP got all the patents and will be on the FDA's Orange Book eventually, imo.
icon url

survivor1x

12/22/19 11:08 AM

#256602 RE: Bright Boy #256593

You obviously haven't been here long. There are plenty of patents. Just like Taxol is isolated from tree and procecced dcvax is isolated from a different living organism Nd procesded.

So I guess the shorts are afraid the the therapy works and now they moved on to dispute its patentability. Next it will be the cost or the insurablility. What else am I missing?
icon url

hyperopia

12/22/19 11:37 AM

#256604 RE: Bright Boy #256593

BrightBoy, “As of December 31, 2018, we have over 190 issued patents and more than 65 pending patent applications worldwide, grouped into 12 patent families. Of these, 181 issued patents and 35 pending patent applications directly relate to our DCVax products. In the United States and Europe, some of our patents and applications relate to the composition and use of products, while other patents and applications relate to other aspects such as manufacturing and quality control. For example, in the United States, we have four issued and seven pending patent applications that relate to the composition and/or use of our DCVax products. We also have other U.S patents and applications that cover, among other things, quality control for DCVax and an automated system which we believe will help enable the scale-up of production for large numbers of patients on a cost-effective basis. Similarly, in Europe, we have five patents issued by and six pending patent applications with the European Patent Office (“EPO”) that cover our DCVax products, and other patents and applications that cover aspects such as manufacturing and quality control, and the automated system. In Japan, we have seven issued patents and three pending patent applications relating to our DCVax products, as well as manufacturing related patents. Patents have been granted and are pending in other foreign jurisdictions which may be potential future markets for our DCVax products.
 
During 2018, two new patents were issued to us as part of our worldwide patent portfolio. The newly issued patents cover methods and devices for manufacturing dendritic cells related to our DCVax products, as well as encompassing certain dendritic cell compositions for direct injection into patient tumors related to DCVax-Direct.
 
During 2017, six new patents were issued to us as part of our worldwide patent portfolio. The newly issued patents cover a variety of subject matter, including certain processes and methods for manufacturing and for enhancing the potency of dendritic cells related to our DCVax products, as well as encompassing certain dendritic cell compositions for direct injection into patient tumors related to DCVax-Direct. 
 
The expiration dates of the issued U.S. patents involved in our current business range from 2022 to 2026. The expiration dates of the issued European patents involved in our current business range from 2022 to 2024. For some of the earlier dates, we plan to seek extensions of the patent life, and believe we have reasonable grounds for doing so.”

https://www.sec.gov/Archives/edgar/data/1072379/000114420419017803/tv517288_10k.htm